Plasma biomarkers in chronic single moderate–severe traumatic brain injury
Brain · 2024
DOI: 10.1093/brain/awae255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2024. Verfasst von Gershon Spitz und 11 weiteren Autor:innen. Beteiligte Einrichtung: Monash-Epworth Rehabilitation Research Centre, School of Psychological Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University,…. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Biomarkers, tau Proteins, Ubiquitin Thiolesterase. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, NHMRC Early Career Fellowship.
Abstract (Originalsprache)
Blood biomarkers are an emerging diagnostic and prognostic tool that reflect a range of neuropathological processes following traumatic brain injury (TBI). Their effectiveness in identifying long-term neuropathological processes after TBI is unclear. Studying biomarkers in the chronic phase is vital because elevated levels in TBI might result from distinct neuropathological mechanisms during acute and chronic phases. Here, we examine plasma biomarkers in the chronic period following TBI and their association with amyloid and tau PET, white matter microarchitecture, brain age and cognition. We recruited participants ≥40 years of age who had suffered a single moderate–severe TBI ≥10 years previously between January 2018 and March 2021. We measured plasma biomarkers using single molecule array technology [ubiquitin C-terminal hydrolase L1 (UCH-L1), neurofilament light (NfL), tau, glial fibrillary acidic protein (GFAP) and phosphorylated tau (P-tau181)]; PET tracers to measure amyloid-β (18F-NAV4694) and tau neurofibrillary tangles (18F-MK6240); MRI to assess white matter microstructure and brain age; and the Rey Auditory Verbal Learning Test to measure verbal-episodic memory. A total of 90 post-TBI participants (73% male; mean = 58.2 years) were recruited on average 22 years (range = 10–33 years) post-injury, and 32 non-TBI control participants (66% male; mean = 57.9 years) were recruited. Plasma UCH-L1 levels were 67% higher {exp(b) = 1.67, P = 0.018, adjusted P = 0.044, 95% confidence interval (CI) [10% to 155%], area under the curve = 0.616} and P-tau181 were 27% higher {exp(b) = 1.24, P = 0.011, adjusted P = 0.044, 95% CI [5% to 46%], area under the curve = 0.632} in TBI participants compared with controls. Amyloid and tau PET were not elevated in TBI participants. Higher concentrations of plasma P-tau181, UCH-L1, GFAP and NfL were significantly associated with worse white matter microstructure but not brain age in TBI participants. For TBI participants, poorer verbal-episodic memory was associated with higher concentration of P-tau181 {short delay: b = −2.17, SE = 1.06, P = 0.043, 95% CI [−4.28, −0.07]; long delay: bP-tau = −2.56, SE = 1.08, P = 0.020, 95% CI [−4.71, −0.41]}, tau {immediate memory: bTau = −6.22, SE = 2.47, P = 0.014, 95% CI [−11.14, −1.30]} and UCH-L1 {immediate memory: bUCH-L1 = −2.14, SE = 1.07, P = 0.048, 95% CI [−4.26, −0.01]}, but was not associated with functional outcome. Elevated plasma markers related to neuronal damage and accumulation of phosphorylated tau suggest the presence of ongoing neuropathology in the chronic phase following a single moderate–severe TBI. Plasma biomarkers were associated with measures of microstructural brain disruption on MRI and disordered cognition, further highlighting their utility as potential objective tools to monitor evolving neuropathology post-TBI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monash-Epworth Rehabilitation Research Centre, School of Psychological Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3800, Australia.
- Department of Neuroscience, School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC 3004, Australia.
- Department of Neurology, The Alfred, Melbourne, VIC 3004, Australia.
- Florey Department of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3010, Australia.
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC 3084, Australia.
- Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC 3010, Australia.
ORCID-Profile: Gershon Spitz, Amelia J Hicks, Lucy Vivash, Sandy R Shultz
Förderung
- National Health and Medical Research Council
- NHMRC Early Career Fellowship
Zitieren
APA
Spitz, G., Hicks, A. J., McDonald, S. J., Dore, V., Krishnadas, N., O'Brien, T. J., O'Brien, W. T., Vivash, L., Law, M., Ponsford, J. L., Rowe, C., & Shultz, S. R. (2024). Plasma biomarkers in chronic single moderate–severe traumatic brain injury. Brain. https://doi.org/10.1093/brain/awae255
Vancouver
Spitz G, Hicks AJ, McDonald SJ, Dore V, Krishnadas N, O'Brien TJ, et al. Plasma biomarkers in chronic single moderate–severe traumatic brain injury. Brain. 2024. doi:10.1093/brain/awae255
BibTeX
@article{Spitz2024,
author = {Spitz, Gershon and Hicks, Amelia J and McDonald, Stuart J and Dore, Vincent and Krishnadas, Natasha and O'Brien, Terence J and O'Brien, William T and Vivash, Lucy and Law, Meng and Ponsford, Jennie L and Rowe, Christopher and Shultz, Sandy R},
title = {Plasma biomarkers in chronic single moderate–severe traumatic brain injury},
journal = {Brain},
year = {2024},
doi = {10.1093/brain/awae255}
}
EUVIMED